BMS at ESMO 2020
Continuing our pursuit of scientific advancement for people with cancer
Intended for U.S. scientific audiences only.
he European Society for Medical Oncology (ESMO) annual meeting is a critical hub for scientific exchange, and despite the challenges of the past year, our commitment to collaborating with the community and pursuing innovative solutions for patients with cancer remains steadfast. We look forward to exploring the latest research approaches and sharing progress for people affected by cancer.
Hear from our chief medical officer of Global Drug Development, Samit Hirawat, M.D., about our commitment to working together to transform outcomes for people with cancer.
Our Data at ESMO
Read more about our key data being presented at the meeting.
- Phase 3 data for esophageal and gastroesophageal cancer in the adjuvant setting
- First presentation of results for new Phase 3 data in gastric and esophageal cancers
- First presentation of results for a new combination in advanced renal cell carcinoma, in partnership with Exelixis
- Four-year survival data for our dual immunotherapy in advanced renal cell carcinoma
- Preview our ESMO data in a range of cancers from renal cell carcinoma to gastric cancers
We are working every day to develop innovative therapies for people affected by cancer. Learn about our recent advances and what we have on the horizon.
We are researching the role immunotherapy may play in improving patient outcomes when used in earlier stages of a patient’s disease. Hear more from our development lead of Gastrointestinal Cancers, Ian Waxman, M.D.
The needs of patients with lung cancer are unique, which is why we’re exploring a variety of treatment approaches. Learn from our vice president and head of Oncology Clinical Development, Sabine Maier, M.D.
Learn about our comprehensive approach to cancer research across the biological spectrum, exploring various modalities, research approaches and important areas of focus.
Continuing Oncology Advancements During COVID-19
The work done by the entire medical community inspires us to do our part for people living with cancer every day, but especially during these challenging and unpredictable times.
Leaders from BMS and the oncology advocacy community discuss the immediate and long-term impacts for cancer patients as a result of the COVID-19 pandemic.
Learn more about BMS’ commitment to people living with blood cancer from our vice president of Hematology Global Medical Affairs, Diane McDowell, M.D.
Our research at ESMO this year spans 15 different types of cancer and multiple therapeutic modalities. Learn more about some of them below.